Clinical Trial: A Study To Evaluate The Safety Of CMTX-101 In People With Cystic Fibrosis
Study Status: COMPLETED
Recruit Status: COMPLETED
Condition: Persistent Infection
Study Type: INTERVENTIONAL
Official Title: A Phase 1b/2a Study To Evaluate The Safety Of CMTX-101 In Combination With Inhaled Antibiotics In People With Cystic Fibrosis Chronically Infected With Pseudomonas Aeruginosa
Brief Summary:
CMTX-101 is a bacterial biofilm disrupting monoclonal antibody being developed as an adjunctive therapy to standard of care antibiotics.The goal of this clinical trial is to assess the safety and tolerability of CMTX-101 in people with cystic fibrosis (pwCF).The main questions the study aims to answer are:Are single doses of CMTX-101 IV infusion safe and toleratedWhat is the pharmacokinetic (PK) profile of single doses of CMTX-101Do single doses of CMTX-101 induce development of anti-drug antibodies (ADA) and…
Read more